1 withdrawn. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Withdrawn 1 |
Follow ReST Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM) Fluoroethylnormemantine (FENM) - PTSD, Alzheimer Disease | Phase 1 | Withdrawn | ReST Therapeutics | 2024-05-02 | 2024-05-03 |
Alzheimer Disease (1) · Brain Diseases (1) · Depressive Disorder, Major (1) · Depressive Disorder, Treatment-Resistant (1) · Stress Disorders, Post-Traumatic (1)
Belgium (1)